Communiqués Amgen Inc.

Actions

AMGN

US0311621009

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 18/06/2026			Varia. 5j.	Varia. 1 janv.
337,60 ^USD	-1,19 %		-0,04 %	+3,14 %

18/06	Amgen : la diversification et le pipeline de développement soutiennent l'optimisme de RBC	MT
15/06	AMGEN INC. : Mizuho Securities persiste à l'achat	ZM

Communiqués

07/06	AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS	PR
04/06	AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE	PR
04/06	Bob Bradway on AI: Reimagining the Future of Biotechnology	PU
03/06	AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026	PR
01/06	Amgen : EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER	PU
29/05	AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE	PR
20/05	Amgen : Approach to AI-Enabled Clinical Development	PU
19/05	AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH	PR
16/05	Amgen : Statement on TAVNEOS® (avacopan)	PU
15/05	Amgen : 2026 Annual Meeting of Stockholders Presentation Non GAAP Reconciliations	PU
12/05	Amgen : The Story of Maridebart Cafraglutide (MariTide)	PU
07/05	AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE	PR
06/05	Inside Amgen’s Next-Generation Labs: Powering Faster, Smarter Small Molecule Drug Discovery	PU
04/05	AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR	PR
01/05	Amgen : C O R R E C T I O N Amgen/	PU
01/05	Amgen : Highlights from Amgen's 2026 First Quarter Earnings Report	PU
30/04	Amgen : Q1 2026 Earnings Slides FINAL 04.30.26	PU
30/04	Amgen: Q1 Earnings Snapshot	AQ
30/04	/C O R R E C T I O N -- Amgen/	PR
29/04	Biocon Launches Denosumab Biosimilars	AQ
27/04	AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS	AQ
24/04	AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS	PR
22/04	AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER	PR
13/04	Amgen And Shanghai Henlius/Organon Settle Denosumab BPCIA Litigation	AQ
06/04	AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE	PR